During the last year, we have seen a substantial increase in the number of studies that are being conducted on cannabis.
The purpose of this study is to learn if medical cannabis helps people who currently take opioid pain medication to treat chronic pain and Jefferson hopes to learn if medical cannabis could replace opioids for people who are struggling with opioid use disorder or opioid dependency.
Early research that is being conducted on medical cannabis has been positive and shows the potential it has to treat people who are dependent on opioids.
Over the next year, we expect companies and research institutions to publish more research on the medical benefits of the cannabis.
Last month, Khiron reported that a study being conducted by Project Twenty 21 showed that medical cannabis dramatically improves quality of life for people who suffer from conditions like chronic pain, Multiple Sclerosis, Tourette’s Syndrome and post-traumatic-stress disorder .
Through Project Twenty21, eligible patients can access affordable medical cannabis treatment, .
According to the National Institute for Clinical Excellence , there is little or no evidence that commonly prescribed drugs, such as benzodiazepines or opioids, make any difference to people’s quality of life, pain or psychological distress.
Project Twenty21’s study showed a 50% increase in patients’ self-reported health and ability to lead a more normal life as well as significant improvements in patients’ ability to manage debilitating secondary conditions such as anxiety, insomnia and depression.
Last month, Ethos announced the official launch of an opiate-use study with the university to assess the viability of medical cannabis as an opioid replacement therapeutic aid.
The university hopes to determine if medical cannabis could replace opioids for those struggling with opioid use disorder or opioid dependency and we are favorable on the impact that positive results could have on the cannabis sector.
Pursuant to an agreement between StoneBridge Partners LLC and Khiron Life Sciences Inc.
All information that we provide is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.